Generic Price Competition For Specialty Drugs: Too Little, Too Late?
- PMID: 29733710
- DOI: 10.1377/hlthaff.2017.1684
Generic Price Competition For Specialty Drugs: Too Little, Too Late?
Abstract
The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected price reductions, shifts in prescribing toward more expensive brand-name treatments, and limited uptake of the generic product.
Keywords: Access To Care; Cost of Health Care; Health Spending; Pharmaceuticals.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources